XTX Topco Ltd Purchases 6,516 Shares of Immunocore Holdings plc (NASDAQ:IMCR)

XTX Topco Ltd lifted its holdings in Immunocore Holdings plc (NASDAQ:IMCR) by 72.9% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 15,459 shares of the company’s stock after buying an additional 6,516 shares during the period. XTX Topco Ltd’s holdings in Immunocore were worth $481,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the stock. Envestnet Asset Management Inc. boosted its holdings in shares of Immunocore by 0.9% in the second quarter. Envestnet Asset Management Inc. now owns 70,571 shares of the company’s stock valued at $2,392,000 after purchasing an additional 606 shares during the period. Hennion & Walsh Asset Management Inc. grew its holdings in shares of Immunocore by 6.5% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 22,622 shares of the company’s stock valued at $767,000 after buying an additional 1,390 shares during the last quarter. Exchange Traded Concepts LLC increased its holdings in shares of Immunocore by 40.4% in the third quarter. Exchange Traded Concepts LLC now owns 5,075 shares of the company’s stock valued at $158,000 after purchasing an additional 1,461 shares during the period. Assetmark Inc. boosted its holdings in shares of Immunocore by 6.5% in the 3rd quarter. Assetmark Inc. now owns 30,555 shares of the company’s stock valued at $951,000 after acquiring an additional 1,878 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of Immunocore by 69.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,433 shares of the company’s stock valued at $231,000 after buying an additional 3,053 shares during the last quarter. 84.50% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Immunocore in a research note on Monday, September 9th. HC Wainwright restated a “buy” rating and set a $100.00 price target on shares of Immunocore in a report on Thursday, October 24th. UBS Group initiated coverage on shares of Immunocore in a research report on Thursday, October 24th. They set a “sell” rating and a $24.00 price objective for the company. Mizuho downgraded Immunocore from an “outperform” rating to a “neutral” rating and dropped their target price for the company from $72.00 to $38.00 in a research report on Monday, November 11th. Finally, Morgan Stanley reiterated an “equal weight” rating and issued a $35.00 target price (down from $74.00) on shares of Immunocore in a report on Friday. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $65.64.

Immunocore Stock Performance

Shares of NASDAQ IMCR opened at $28.91 on Friday. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76. The company has a market capitalization of $1.45 billion, a P/E ratio of -30.43 and a beta of 0.73. The business’s 50-day moving average price is $32.28 and its two-hundred day moving average price is $35.28. Immunocore Holdings plc has a one year low of $28.27 and a one year high of $76.98.

Immunocore (NASDAQ:IMCR) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.50. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. The business had revenue of $80.25 million during the quarter, compared to analysts’ expectations of $78.94 million. During the same quarter in the previous year, the firm earned ($0.59) EPS. The firm’s revenue was up 23.7% compared to the same quarter last year. Analysts anticipate that Immunocore Holdings plc will post -0.94 earnings per share for the current fiscal year.

Immunocore Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.